Achieving Equitable Cardiovascular Care for All: ACC Board of Trustees Health Equity Task Force Action Plan.

Advancements in cardiovascular (CV) disease management are notable, yet health inequities prevail, associated with increased morbidity and mortality noted among non-Hispanic African Americans in the United States. The 2002 Institute of Medicine Report revealed ongoing racial and ethnic health care disparities, spearheading a deeper understanding of the social determinants of health and systemic racism to develop strategies for CV health equity (HE). This article outlines the strategic HE approach of the American College of Cardiology, comprising 6 strategic equity domains: workforce pathway inclusivity, health care, data, science, and tools; education and training; membership, partnership, and collaboration; advocacy and policy; and clinical trial diversity. The American College of Cardiology's Health Equity Task Force champions the improvement of patients' lived experiences, population health, and clinician well-being while reducing health care costs-the Quadruple Aim of Health Equity. Thus, we examine multifaceted HE interventions and provide evidence for scalable real-world interventions to promote equitable CV care.

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

Dr Echols has a consultation/advisory committee role for Amgen, Bayer, Boehringer Ingelheim, Merck, Regeneron, Novo Nordisk, and Novartis; and is on the Data Safety Monitoring Committees of REACT-AF. Dr Bozkurt has a consultation/advisory committee role for Abiomed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Occlutech, Regeneron, Roche, Sanofi, scPharmaceuticals, Vifor, and Zoll/ Respicardia; and serves on the Data Safety Monitoring Committees of Liva Nova, Cardurion, Novo Nordisk, and Renovacor. Dr Ogunniyi has received institutional research grant support from AstraZeneca, 10.13039/100001003Boehringer Ingelheim, Cardurion Pharmaceuticals, and 10.13039/100004319Pfizer; and and serves on a clinical trial steering committee for 10.13039/100008272Novartis, all outside and not relevant to the contents of this manuscript. Dr Levy has a consultation/advisory committee role for Bayer, Beckman Coulter, BTG Specialty Pharmaceuticals, Cardionomics, Heart Beam, Hemisens, Medscape, Moderna, Pathfast, People.Health, Quidel Ortho, and Roche Diagnostics; is on the Data Safety Monitoring Board for Life Recovery Systems; has ownership/partnership with Alerje, Emergencies in Medicine, and My Patient Insight; and has received from 10.13039/100004319Pfizer and COVID-19 Surveillance Testing for Quest Diagnostics. Dr Bailey has a consultation/advisory board role for Novo Nordisk, OptumRX. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.